Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILI and Targeted Gene Therapy for Advanced Extremity Melanoma
NCT01531244Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 2 trial of Ad5/3-Δ24 in melanoma, sponsored by Washington University School of Medicine. Planned start Dec 2014; status: withdrawn.
02
Drugs
Ad5/3-Δ24
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01531244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531244.